Johnson & Johnson $JNJ Shares Sold by Sheets Smith Wealth Management

Sheets Smith Wealth Management lessened its position in Johnson & Johnson (NYSE:JNJ) by 19.3% during the third quarter, Holdings Channel reports. The fund owned 10,542 shares of the company’s stock after selling 2,522 shares during the quarter. Sheets Smith Wealth Management’s holdings in Johnson & Johnson were worth $1,955,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Clark Asset Management LLC boosted its position in Johnson & Johnson by 51.6% during the 2nd quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock worth $1,357,000 after acquiring an additional 3,025 shares during the period. Treasurer of the State of North Carolina raised its stake in shares of Johnson & Johnson by 8.3% during the second quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock valued at $188,638,000 after purchasing an additional 94,957 shares in the last quarter. Avanza Fonder AB lifted its holdings in Johnson & Johnson by 2.9% in the second quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock worth $35,842,000 after purchasing an additional 6,566 shares during the period. Talbot Financial LLC grew its position in Johnson & Johnson by 4.6% in the 3rd quarter. Talbot Financial LLC now owns 138,424 shares of the company’s stock valued at $25,667,000 after buying an additional 6,143 shares in the last quarter. Finally, Winnow Wealth LLC acquired a new position in Johnson & Johnson during the 2nd quarter valued at about $295,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Bank of America increased their price target on Johnson & Johnson from $204.00 to $220.00 and gave the company a “neutral” rating in a research note on Monday, December 15th. Argus set a $210.00 price objective on Johnson & Johnson in a research note on Wednesday, October 15th. Guggenheim raised their target price on Johnson & Johnson from $206.00 to $227.00 and gave the company a “buy” rating in a research note on Friday, December 5th. Finally, Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 14th. Four analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $210.25.

Johnson & Johnson Trading Down 0.1%

NYSE:JNJ opened at $207.54 on Friday. The stock has a fifty day simple moving average of $199.67 and a 200 day simple moving average of $181.03. The firm has a market capitalization of $500.02 billion, a price-to-earnings ratio of 20.03, a price-to-earnings-growth ratio of 2.25 and a beta of 0.36. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $215.18. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion for the quarter. Sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.